Biotech · Private company
VLP Therapeutics
Track this companyFree. Adds VLP Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials32 recruiting or active
Pipeline programs11From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline11
- 15 microgram VLPM01Phase 1 · Malaria,FalciparumClinicalTrials.gov · fetched Nov 12, 2026
- 30 microgram VLPM01Phase 1 · Malaria,FalciparumClinicalTrials.gov · fetched Nov 12, 2026
- 5 microgram VLPM01Phase 1 · Malaria,FalciparumClinicalTrials.gov · fetched Nov 12, 2026
- Pembrolizumab (KEYTRUDA®)Phase 1 · Head and Neck Cancers- Squamous CellClinicalTrials.gov · fetched Nov 12, 2026
- Plasmodium falciparum challengePhase 1 · Malaria,FalciparumClinicalTrials.gov · fetched Nov 12, 2026
- rDEN3Delta30Phase 1 · Randomised Clinical TrialClinicalTrials.gov · fetched Nov 12, 2026
- VLPDEN-02 1.0 µg (0.25 µg of each VLP) + ALFQ adjuvantPhase 1 · Randomised Clinical TrialClinicalTrials.gov · fetched Nov 12, 2026
- VLPDEN-02 10 µg (2.5 µg of each VLP) + ALFQ adjuvantPhase 1 · Randomised Clinical TrialClinicalTrials.gov · fetched Nov 12, 2026
- VLPDEN-02 100 µg (25 µg of each VLP) + ALFQ adjuvantPhase 1 · Randomised Clinical TrialClinicalTrials.gov · fetched Nov 12, 2026
- VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection)Phase 1 · Head and Neck Cancers- Squamous CellClinicalTrials.gov · fetched Nov 12, 2026
- VRP-encapsulated saRNA encoding IL-12 (3 x 10^8 viral particles per injection)Phase 1 · Head and Neck Cancers- Squamous CellClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy AdultsPHASE1 · NOT_YET_RECRUITING · started Jan 4, 2027ClinicalTrials.gov NCT07831473 · fetched Nov 12, 2026
- Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck CancerPHASE1 · RECRUITING · started May 13, 2025ClinicalTrials.gov NCT06736379 · fetched Nov 12, 2026
- To Assess the Safety, Immunogenicity and Efficacy of VLPM01 in Healthy, Malaria-Naïve VolunteersPHASE1 · COMPLETED · started Mar 13, 2019ClinicalTrials.gov NCT03867331 · fetched Nov 12, 2026